NCT00705406

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 405 (actual)
• Sponsor: BioCryst Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.

Conditions

• Acute, Uncomplicated Human Influenza

Interventions

Type	Name	Description
DRUG	Peramivir	600 mg peramivir administered as bilateral 2-mL intramuscular injection
DRUG	Placebo	Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-04-01
• Completion: 2009-10-01
• First posted: 2008-06-26
• Last updated: 2015-02-16
• Results posted: 2015-02-16

Locations

123 sites across 4 countries: United States, Australia, New Zealand, South Africa